Financials in USD. Standardized financial statements.
A compact view of how Regeneron Pharmaceuticals, Inc. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $14.34B | $14.20B | $13.12B | $12.17B | $16.07B | $8.50B | $6.56B | $6.71B | $5.87B | $4.86B |
| Revenue Growth? | +1.0% | +8.3% | +7.8% | -24.3% | +89.1% | +29.6% | -2.3% | +14.3% | +20.8% | 0.0% |
| Cost of Revenue? | $2.10B | $1.97B | $2.24B | $1.71B | $2.72B | $1.36B | $975.40M | $582.30M | $542.53M | $404.44M |
| Gross Profit? | $12.24B | $12.23B | $10.87B | $10.47B | $13.35B | $7.14B | $5.58B | $6.13B | $5.33B | $4.46B |
| Gross Margin? | +85.4% | +86.1% | +82.9% | +86.0% | +83.1% | +84.0% | +85.1% | +91.3% | +90.8% | +91.7% |
| Operating Expenses? | $8.66B | $8.24B | $6.52B | $5.08B | $4.40B | $3.56B | $3.37B | $3.59B | $3.25B | $3.13B |
| Operating Income? | $3.58B | $3.99B | $4.35B | $5.39B | $8.95B | $3.58B | $2.21B | $2.53B | $2.08B | $1.33B |
| EBITDA? | $5.82B | $5.32B | $4.69B | $5.26B | $9.67B | $4.10B | $2.67B | $2.73B | $2.25B | $1.44B |
| Income Before Tax | $5.23B | $4.78B | $4.20B | $4.86B | $9.33B | $3.81B | $2.43B | $2.55B | $2.08B | $1.33B |
| Income Tax Expense | $725.80M | $367.30M | $245.70M | $520.40M | $1.25B | $297.20M | $313.30M | $109.10M | $880.00M | $434.29M |
| Net Income? | $4.50B | $4.41B | $3.95B | $4.34B | $8.08B | $3.51B | $2.12B | $2.44B | $1.20B | $895.52M |
| EPS? | $43.07 | $40.90 | $37.05 | $40.51 | $76.40 | $32.65 | $19.38 | $21.29 | $11.27 | $8.55 |
| Diluted EPS? | $41.48 | $38.34 | $34.77 | $38.22 | $71.97 | $30.52 | $18.46 | $21.29 | $10.34 | $7.70 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality